Skip to content Skip to footer


The company focuses on the development of first-line anticancer compounds that induce cancer cells apoptosis (programmed death). To do this, we seek to bring Dr. Hajji’s promising research to clinical phases in humans, developing a new future for oncology, thanks to innovative new therapies that address the medical needs which are not met today.

The first drug candidate is set to begin clinical trials as a first-line therapy for non-small cell lung cancer.

It is also developing the innovative AI system KEYZELL OPS, which aims to be the future of precision medicine in oncology, choosing personalised treatments for cancer patients who do not respond to traditional treatments, offering the most appropriate option for the cancer, in the right order and at the ideal time according to the characteristics of each patient.